Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15640%2F24%3A73625511" target="_blank" >RIV/61989592:15640/24:73625511 - isvavai.cz</a>

Alternative codes found

RIV/61989592:15110/24:73625511 RIV/61989592:15310/24:73625511

Result on the web

<a href="https://www.mdpi.com/2072-6694/16/15/2630" target="_blank" >https://www.mdpi.com/2072-6694/16/15/2630</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/cancers16152630" target="_blank" >10.3390/cancers16152630</a>

Result language

angličtina

Original language name

Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event

Original language description

Simple Summary Lck is an important kinase that plays a key role in the physiological responses of T lymphocytes as well as in several other tissues such as the lung, intestine, brain, endometrium, and prostate. It can be found bound to the cell membrane, free in the cytosol, and even in the nucleus as it interacts with different proteins involved in various biological responses. Additionally, Lck is considered a proto-oncogene. Phosphatases and the Csk kinase control Lck activity: phosphatases can open and inactivate the structure, while Csk can only close it. The activation and modifications of Lck differ between normal and pathological conditions, such as cancer, allergy, autoimmunity, and graft vs. host disease. These differences may lead to new targets for pharmacological therapy. This overview briefly summarizes the characteristics and modulations of the enzyme.Abstract Lck, a member of the Src kinase family, is a non-receptor tyrosine kinase involved in immune cell activation, antigen recognition, tumor growth, and cytotoxic response. The enzyme has usually been linked to T lymphocyte activation upon antigen recognition. Lck activation is central to CD4, CD8, and NK activation. However, recently, it has become clearer that activating the enzyme in CD8 cells can be independent of antigen presentation and enhance the cytotoxic response. The role of Lck in NK cytotoxic function has been controversial in a similar fashion as the role of the enzyme in CAR T cells. Inhibiting tyrosine kinases has been a highly successful approach to treating hematologic malignancies. The inhibitors may be useful in treating other tumor types, and they may be useful to prevent cell exhaustion. New, more selective inhibitors have been documented, and they have shown interesting activities not only in tumor growth but in the treatment of autoimmune diseases, asthma, and graft vs. host disease. Drug repurposing and bioinformatics can aid in solving several unsolved issues about the role of Lck in cancer. In summary, the role of Lck in immune response and tumor growth is not a simple event and requires more research.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cancers

ISSN

2072-6694

e-ISSN

—

Volume of the periodical

16

Issue of the periodical within the volume

15

Country of publishing house

CH - SWITZERLAND

Number of pages

25

Pages from-to

2630

UT code for WoS article

001287077200001

EID of the result in the Scopus database

2-s2.0-85200834695